Evidence map›Paper›PMID 39105852›Full record

ArticleMolecular biology reports2024

The role of ceranib-2 and its nanoform on the decrease of telomerase levels in human non-small cell cancer.

Mustafa Cengiz, Canan Vejselova Sezer, Bahri Gür, Alpaslan Bayrakdar, Hüseyin İzgördü, Filiz Alanyalı, Cem Öziç, Hatice Mehtap Kutlu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mustafa CengizDepartment of Elementary Education, Faculty of Education, Siirt University, Siirt, 56100, Türkiye. m.cengiz@siirt.edu.tr.
Canan Vejselova SezerDepartment of Biology, Faculty of Science, Eskişehir Technical University, Eskişehir, 26470, Türkiye.
Bahri GürDepartment of Biochemistry, Faculty of Sciences and Arts, Iğdır University, Iğdır, 76300, Türkiye. bahri.gur@igdir.edu.tr.
Alpaslan BayrakdarVocational School of Higher Education for Healthcare Services, Iğdır University, Iğdır, 76000, Türkiye.
Hüseyin İzgördüDepartment of Biology, Faculty of Science, Eskişehir Technical University, Eskişehir, 26470, Türkiye.
Filiz AlanyalıDepartment of Biology, Faculty of Science, Eskişehir Technical University, Eskişehir, 26470, Türkiye.
Cem ÖziçDepartment of Medical Biology, Kafkas University, Medicine Faculty, Ahmet Arslan Street, Kars, 36100, Türkiye.
Hatice Mehtap KutluDepartment of Biology, Faculty of Science, Eskişehir Technical University, Eskişehir, 26470, Türkiye.

Funding

Eskişehir Teknik Üniversitesi 21GAP109Eskişehir Teknik Üniversitesi 21GAP112
6 · The paper itself

Abstract

backgroundCeranib-2, an acid ceramidase (AC) inhibitor, can inhibit cancer cell proliferation and tumor development. However, poor water solubility and low cellular bioavailability limit its efficacy in cancer treatment. METHODS AND

resultsThis study aimed to investigate the cell death induced by ceranib-2 and its solid lipid nanoformulation (ceranib-2-SLN) produced by the hot homogenization technique and the synergistic relationship between ceramide and telomerase in vitro and in silico. Furthermore, this study proved the possible mechanism of ceranib-2-induced AC inhibition by in silico studies. The effective cytotoxic concentrations of ceranib-2, telomerase level, and changes in ceramide levels were measured by MTT colorimetric cytotoxicity assay, ELISA, and LC/MS/MS methods, respectively. TEM results showed that ceranib-2-SLN was 13-fold smaller than the size of ceranib-2. Ceranib-2 and ceranib-2-SLN had IC

conclusionsCeranib-2-SLN was discovered to be more cytotoxic on cancer cells than ceranib-2, suggesting that it could be a promising option for the development of a new anti-cancer agent.

Indexed as

TelomeraseA549 CellsAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalCeramidesHumansNanoparticlesAntineoplastic AgentsCeramidesTelomeraseAcid ceramidase inhibitionCeramideCytotoxicityin silicoTelomerase

Identifiers

PMID39105852

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.